GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Collegium Pharmaceutical Inc (NAS:COLL) » Definitions » Cyclically Adjusted PB Ratio

COLL (Collegium Pharmaceutical) Cyclically Adjusted PB Ratio : 5.32 (As of May. 27, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Collegium Pharmaceutical Cyclically Adjusted PB Ratio?

As of today (2025-05-27), Collegium Pharmaceutical's current share price is $29.48. Collegium Pharmaceutical's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $5.54. Collegium Pharmaceutical's Cyclically Adjusted PB Ratio for today is 5.32.

The historical rank and industry rank for Collegium Pharmaceutical's Cyclically Adjusted PB Ratio or its related term are showing as below:

COLL' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 4.75   Med: 6.82   Max: 8.81
Current: 5.3

During the past years, Collegium Pharmaceutical's highest Cyclically Adjusted PB Ratio was 8.81. The lowest was 4.75. And the median was 6.82.

COLL's Cyclically Adjusted PB Ratio is ranked worse than
83.71% of 669 companies
in the Drug Manufacturers industry
Industry Median: 1.82 vs COLL: 5.30

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Collegium Pharmaceutical's adjusted book value per share data for the three months ended in Mar. 2025 was $7.296. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $5.54 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Collegium Pharmaceutical Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Collegium Pharmaceutical's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Collegium Pharmaceutical Cyclically Adjusted PB Ratio Chart

Collegium Pharmaceutical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 6.83 5.57

Collegium Pharmaceutical Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.35 6.81 8.04 5.57 5.38

Competitive Comparison of Collegium Pharmaceutical's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Collegium Pharmaceutical's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Collegium Pharmaceutical's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Collegium Pharmaceutical's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Collegium Pharmaceutical's Cyclically Adjusted PB Ratio falls into.


;
;

Collegium Pharmaceutical Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Collegium Pharmaceutical's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=29.48/5.54
=5.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Collegium Pharmaceutical's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Collegium Pharmaceutical's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=7.296/134.9266*134.9266
=7.296

Current CPI (Mar. 2025) = 134.9266.

Collegium Pharmaceutical Quarterly Data

Book Value per Share CPI Adj_Book
201506 4.951 100.684 6.635
201509 4.522 100.392 6.078
201512 4.102 99.792 5.546
201603 5.177 100.470 6.952
201606 4.193 101.688 5.564
201609 3.151 101.861 4.174
201612 4.594 101.863 6.085
201703 3.882 102.862 5.092
201706 3.231 103.349 4.218
201709 3.129 104.136 4.054
201712 3.176 104.011 4.120
201803 2.750 105.290 3.524
201806 2.492 106.317 3.163
201809 2.129 106.507 2.697
201812 2.753 105.998 3.504
201903 2.586 107.251 3.253
201906 2.568 108.070 3.206
201909 2.513 108.329 3.130
201912 2.596 108.420 3.231
202003 4.112 108.902 5.095
202006 4.516 108.767 5.602
202009 4.994 109.815 6.136
202012 5.375 109.897 6.599
202103 4.830 111.754 5.831
202106 7.124 114.631 8.385
202109 7.216 115.734 8.413
202112 6.030 117.630 6.917
202203 5.780 121.301 6.429
202206 5.793 125.017 6.252
202209 5.838 125.227 6.290
202212 5.756 125.222 6.202
202303 5.197 127.348 5.506
202306 5.784 128.729 6.062
202309 5.410 129.860 5.621
202312 6.132 129.419 6.393
202403 6.793 131.776 6.955
202406 6.701 132.554 6.821
202409 7.269 133.029 7.373
202412 7.279 133.157 7.376
202503 7.296 134.927 7.296

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Collegium Pharmaceutical  (NAS:COLL) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Collegium Pharmaceutical Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Collegium Pharmaceutical's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Collegium Pharmaceutical Business Description

Traded in Other Exchanges
Address
100 Technology Center Drive, Stoughton, MA, USA, 02072
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
Executives
Tupper Colleen officer: EVP & Chief Financial Officer C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
Scott Dreyer officer: EVP & Chief Commercial Officer 780 DEDHAM STREET, SUITE 800, CANTON MA 02021
Shirley R. Kuhlmann officer: EVP and General Counsel 780 DEDHAM STREET, SUITE 800, CANTON MA 02021
Thomas B Smith officer: EVP and Chief Medical Officer BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE SUITE 225, RALEIGH NC 27612
Garen G Bohlin director C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER STREET, WALTHAM MA 02451
Joseph Ciaffoni director, officer: President and CEO 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
Michael Thomas Heffernan director C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
John Gordon Freund director 125 UNIVERSITY AVE., C/O SKYLINE VENTURES, PALO ALTO CA 94301
Rita J. Balice-gordon director C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
John A. Fallon director C/O INSULET CORPORATION, 9 OAK PARK DRIVE, BEDFORD MA 01730
Gwen A Melincoff director C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Gino Santini director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Neil F. Mcfarlane director C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130
Richard Malamut officer: EVP and Chief Medical Officer 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
Alison B Fleming officer: Vice President, Product Devlp 780 DEDHAM STREET, SUITE 800, CANTON MA 02021